Mobile

A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Sp...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-000646-35

A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Spondyloarthritis Multicentrická, randomizovaná, dvojitě zaslepená studie porovnávající účinnost a bezpečnost pokračující terapie adalimumabem oproti ukončení léčby adalimumabem u pacientů s axiální spondylartritidou bez radiologického průkazu ve stádiu remise

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The objective of this study is to evaluate the efficacy and safety of continuing versus withdrawing therapy with adalimumab 40 mg given every other week (eow) subcutaneously (SC) in maintaining remission in subjects with non-radiographic axial Spondyloarthritis (nr-axSpA).

Critère d'inclusion

  • Axial Spondyloarthritis

Liens